You are here: Industry Insights > Enzyme

News List

The key to a powerful antibiotic's formation now clear WorldPharmaNews
February 07, 2022
A powerful class of antibiotics called carbapenems can circumvent antibiotic resistance thanks to a particular chain of atoms in their structure. Now, a team of researchers from Penn State and Johns Hopkins University...
Cellvera Receives $20M Order for COVID-19 Oral Antiviral Avigan contractpharma
January 25, 2022
Favipiravir is a broad-spectrum oral antiviral drug that targets COVID-19 and 11 other infectious diseases.
Angel Yeast Invests in New Enzyme Project pharmatimes
January 03, 2022
New green manufacturing base will be capable of 5,000 tons annual production output.
Enzyme Replacement Therapy Approved for Late-Onset Pompe Disease drugs
August 11, 2021
Nexviazyme (avalglucosidase alfa-ngpt) was approved for the treatment of the rare inherited disorder late-onset Pompe disease in patients 1 year of age and older, the U.S. Food and Drug Administration announced Friday.
Synthetic Biology Startup Allozymes Raises US $5 Million Seed Round to Deliver Sustainable, Scalable Manufacturing of Natural Ingredients prnasia
July 21, 2021
Allozymes, a Singapore-based, synthetic biology startup, announced today that it has raised US $5 million in a seed financing round led by Xora Innovation, the deep science investment arm of Temasek Holdings.
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder firstwordpharma
June 11, 2021
Codexis, Inc.,today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing
Gene therapy successfully treats rare immunodeficiency in paediatric patients europeanpharmaceuticalreview
May 13, 2021
In three Phase I/II trials an experimental gene therapy caused all but two patients with severe combined immunodeficiency to acquire and retain robust immune function for more than two years.
Researchers discover SARS-CoV-2 inhibitors worldpharmanews
March 05, 2021
A research team of pharmacists at the University of Bonn has discovered two families of active substances that can block the replication of the SARS-CoV-2 coronavirus.
ACE2 protein protects against severe COVID-19 worldpharmanews
December 18, 2020
Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stronger immune response, according to new research from a University of Alberta-led team.
Sekisui Diagnostics Invests in Biopharma CDMO Capacity contractpharma
August 05, 2020
Investing £14.4 million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at its site in Maidstone, Kent.

Previous page 1 2 3 Next page